Skip to main content
. 2018 Dec 27;12(1):165–179. doi: 10.1016/j.stemcr.2018.11.020

Figure 3.

Figure 3

Nocodazole Treatment Does Not Affect Pluripotency of hESCs

(A) Brightfield images of H9 hESCs showing cell morphology after nocodazole release. Scale bars, 400 μm.

(B) qRT-PCR analysis for pluripotency and differentiation markers in H9 hESCs through a time course of 24 hr after nocodazole release. Error bars represent ±SEM of two independent experiments.

(C) qRT-PCR analysis for pluripotency and differentiation markers in H9 hESCs at passage 2, passage 3, and passage 16 after nocodazole treatment. Error bars represent ±SEM of triplicates in an independent experiment.

(D) Representative flow cytometry analysis for OCT4 expression in H9 hESCs through a time course of 24 hr after nocodazole release.

(E) Immunostaining analysis for the expression of pluripotency markers OCT4, NANOG, and SOX2 and differentiation markers BRACHYURY, EOMES, and SOX1 in DMSO- and nocodazole-treated H9 hESCs, two passages after nocodazole release. Scale bar, 200 μm.

See also Figure S2.